Severe epidemic enterovirus respiratory syndrome refers to the acute, often life-threatening respiratory illness caused by Enterovirus D68 (EV-D68) during large-scale outbreaks that have struck repeatedly since 2014. Unlike most enteroviruses, which cause mild cold symptoms or hand-foot-and-mouth disease, EV-D68 can trigger intense bronchospasm and respiratory failure, particularly in children with a history of asthma. The virus circulates in a roughly biennial pattern, and the COVID-19 pandemic scrambled that cycle in ways that made subsequent waves larger and less predictable.
What the Illness Looks Like in Children
The hallmark of severe EV-D68 respiratory disease is rapid-onset wheezing and difficulty breathing that escalates quickly. During the large 2014 U.S. outbreak, the most common symptoms among hospitalized children were shortness of breath (about 84%), cough (81%), and wheezing (70%), while fewer than half had fever. Roughly 59% of hospitalized patients needed intensive care, and about 28% required mechanical ventilation.1The Lancet. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation The picture resembles a catastrophic asthma attack more than a typical viral pneumonia, and that is not a coincidence: the virus has a particular affinity for the airways of children who already have reactive airway disease.
A study of children with EV-D68 infections severe enough to require intensive care found they were significantly more likely than EV-D68-negative children to have a history of asthma or recurrent wheezing (68% versus 42%) and to present with cough (90% versus 63%). Nearly all received albuterol, three-quarters needed intravenous magnesium, a quarter received aminophylline, and 44% required non-invasive ventilatory support such as BiPAP.2PubMed. Severe enterovirus 68 respiratory illness in children requiring intensive care management In the 2024 Colorado outbreak, all ten children who tested positive for EV-D68 were hospitalized, and eight of those ten landed in the ICU, with a median age under five years.3PubMed Central. Return of the Biennial Circulation of Enterovirus D68 in Colorado Children in 2024 Following the Large 2022 Outbreak
The Asthma Connection
EV-D68’s relationship with asthma runs deeper than simply being worse in asthmatic kids. During the 2014 U.S. outbreak, about half of all hospitalized EV-D68 patients had a history of asthma or reactive airway disease, and those with that history were significantly more likely to need intensive care (66%) compared with those without it (51%).4The Lancet. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation A nationwide survey in Japan confirmed that EV-D68 epidemics produce noticeable spikes in asthma hospitalizations and mechanical ventilation use.5PubMed. “Spike” in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A nation-wide survey
Among outpatient children, the clinical range is broader. In one study of 69 EV-D68-positive children, more than half had only upper respiratory tract infections. About a third developed bronchiolitis or an asthma attack, and among the children who wheezed, roughly a quarter were diagnosed with an asthma exacerbation. The children who needed hospital admission were almost all admitted because of asthma attacks specifically.6PubMed. Clinical characteristics of children infected with enterovirus D68 in an outpatient clinic and the association with bronchial asthma There is also a longer-term concern: a large study found that enterovirus infection in children was associated with a meaningfully higher risk of developing asthma later on.7The Pediatric Infectious Disease Journal. Association Between Enterovirus Infection and Asthma in Children
The Biennial Cycle and Post-Pandemic Disruption
EV-D68 has historically surged every other year in late summer and early fall. Surveillance in Lyon, France, between 2010 and 2016 documented 171 infections that followed a clear biennial pattern, peaking in even-numbered years and nearly vanishing in odd ones. Children under five accounted for about 71% of all detected cases.8PubMed Central. Molecular diversity and biennial circulation of enterovirus D68: a systematic screening study in Lyon, France, 2010 to 2016 European-wide data from 2014 to 2024 confirmed the pattern, with detection rates ranging from about 9% during peak years to under 1% in troughs.9PubMed Central. Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024
The COVID-19 pandemic smashed this rhythm. Social distancing, masking, and school closures cut exposure to EV-D68 and other respiratory viruses dramatically during 2020 and 2021.10PubMed Central. Dynamics of Endemic Virus Re-emergence in Children in the USA Following the COVID-19 Pandemic (2022-2023): A Longitudinal Immunoepidemiologic Surveillance Study When restrictions lifted, the virus came roaring back. Europe saw notable surges in 2021, 2022, and 2024, with the 2024 detection rate reaching about 21%, the highest recorded in the surveillance period.11PubMed Central. Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024 In northern Italy, rhinovirus and enterovirus infections climbed from about 13% of positive respiratory tests in 2023–2024 to nearly 46% by 2024–2025 before stabilizing around 42% the following year.12International Journal of Infectious Diseases. Post-pandemic re-establishment of respiratory virus seasonality and molecular epidemiology of Rhinovirus/Enterovirus in Northern Italy: a three-year surveillance study (2023–2026)
The likely explanation is that two years of reduced exposure left a large cohort of young children with no prior immunity to EV-D68, creating a bigger pool of susceptible hosts than a normal biennial cycle would produce. It took several seasons for circulation patterns to settle back toward the old rhythm.
Acute Flaccid Myelitis and the Neurological Threat
The most feared complication of EV-D68 infection is acute flaccid myelitis (AFM), a polio-like paralysis caused by damage to motor neurons in the spinal cord. Surges in AFM cases have coincided with EV-D68 epidemic years both in the U.S. and globally, and the virus has been recovered from respiratory specimens of AFM patients.13PubMed Central. Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality For years, the causal link was debated because the virus was rarely found in cerebrospinal fluid, and no animal model existed. That gap has since narrowed: a mouse model using a clinical isolate from the 2014 epidemic reproduces many key features of human AFM, including viral infection of the spinal cord, death of motor neurons, and progressive paralysis.14PubMed Central. VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis
AFM remains uncommon even during large outbreaks, but when it strikes, outcomes can be devastating. Among children with severe enterovirus-related brainstem and spinal cord involvement who required life support, lasting problems included difficulty swallowing (requiring feeding tubes for a median of over 15 months), respiratory failure needing tracheostomy tubes for a median of about 30 months, and limb weakness or paralysis.15PubMed. Extracorporeal life support for critical enterovirus 71 rhombencephalomyelitis: long-term neurologic follow-up Recovery is slow and often incomplete, which is part of what drives urgency around vaccine research.
How the Virus Enters Cells
Understanding why EV-D68 attacks both lungs and neurons requires a look at how it gets into cells. The virus uses sialic acid, a sugar molecule found on the surface of airway cells, as a landing pad. When EV-D68 binds sialic acid, the interaction triggers a structural shift in the virus that ejects a small fatty-acid-like molecule from a pocket inside the capsid, destabilizing the virus just enough for it to release its genetic material into the cell.16PubMed Central. Sialic acid-dependent cell entry of human enterovirus D68
Sialic acid explains respiratory tropism, but newer strains have evolved to use additional receptors. ICAM-5, a molecule found specifically on neurons, provides a route into nerve cells and helps explain how some strains cause AFM. And a recently identified receptor called MFSD6 is used by a broad range of EV-D68 strains in both respiratory and neuronal cells. The virus can switch between or simultaneously use sialic acid, ICAM-5, and MFSD6, giving it a flexibility that influences which tissues it attacks and how quickly it evolves.17PubMed Central. Enterovirus D68 receptor usage: from static attachment to dynamic entry Recent structural work has shown that MFSD6 carries its own sialic acid residue that slots into the same binding site on the virus, meaning one receptor essentially presents the same molecular key the virus already recognizes, but on a different type of cell.18Nature Communications. A dual-receptor checkpoint primes enterovirus D68 for respiratory cell entry
Immune Evasion and Lung Damage
EV-D68 does not simply overwhelm the lungs with direct viral damage. Much of the harm comes from an exaggerated and dysregulated immune response. In mouse models, infection triggers a flood of inflammatory molecules and draws waves of immune cells into the lungs, causing damage to the delicate barrier that keeps fluid out of the air spaces. The result is pulmonary edema, the accumulation of fluid in the lungs that compounds the breathing difficulty the virus itself already causes.19PubMed. Local immune dysregulation and subsequent inflammatory response contribute to pulmonary edema caused by Enterovirus infection in mice
The virus also plays an active game against the immune system’s antiviral defenses. Early in infection, EV-D68 activates the interferon response, one of the body’s first lines of defense. But as infection progresses, the virus ramps up a host protein called SOCS3 that shuts down interferon signaling, effectively pulling the plug on the immune alarm system just as it is needed most.20PubMed Central. Enterovirus D68 infection upregulates SOCS3 expression to inhibit JAK-STAT3 signaling and antagonize the innate interferon response of the host This two-phase strategy, first provoking an immune overreaction that damages tissue and then suppressing the targeted antiviral arm that could actually clear the virus, helps explain why illness can escalate so quickly in vulnerable children.
Why Diagnosis Is Trickier Than It Looks
One reason EV-D68 flew under the radar for decades is that standard clinical tests struggle to distinguish it from rhinovirus, the common cold virus. The two are genetically similar, and many multiplex respiratory panels lump them into a single “rhinovirus/enterovirus” result without specifying which one is present. During the 2014 U.S. epidemic, researchers found that EV-D68 isolates cross-reacted with rhinovirus on a widely used molecular diagnostic platform, producing positive rhinovirus signals that could mask the true cause of illness.21PLOS ONE. Epidemic 2014 Enterovirus D68 Cross-Reacts with Human Rhinovirus on a Respiratory Molecular Diagnostic Platform
Newer assays have been designed to differentiate the two groups. Approaches using specialized molecular probes or nested PCR with group-specific primers can reliably separate rhinoviruses from enteroviruses in clinical specimens.22PubMed Central. Simultaneous detection and differentiation of human rhino- and enteroviruses in clinical specimens by real-time PCR with locked nucleic Acid probes23PubMed Central. Sensitive detection and differentiation of rhinoviruses and enteroviruses by a nested real-time RT-PCR assay But these are not routinely run in most hospitals. As a result, surveillance data almost certainly undercount EV-D68 infections, which matters for recognizing outbreaks early and understanding how common severe cases really are.
Wastewater as an Early Warning System
One promising surveillance strategy borrows from the COVID-19 playbook. In Niigata City, Japan, during 2024, researchers detected EV-D68 in wastewater about five weeks before hospitalizations for wheezing in children began to climb. Wastewater EV-D68 concentrations correlated positively with pediatric wheezing admissions, and the wastewater data even picked up viral subclades that were never detected in patient samples.24PubMed Central. Prospective use of wastewater surveillance for early detection of enterovirus D68 in community outbreaks among children, Niigata City, Japan, 2024 That kind of lead time could allow hospitals to prepare for surges in pediatric respiratory admissions, stockpile medications, and alert clinicians to test for EV-D68 specifically rather than settling for a generic rhinovirus/enterovirus result.
Treatment Is Mostly Supportive
There is no approved antiviral for EV-D68, so managing severe respiratory cases revolves around aggressive supportive care: bronchodilators, supplemental oxygen, non-invasive ventilation, and in the worst cases, mechanical ventilation or ICU admission. Corticosteroids, the mainstay for typical asthma exacerbations, have shown mixed results overall for viral wheezing in children. However, one trial found that prednisolone significantly shortened time to discharge specifically in children hospitalized with enterovirus-associated wheezing, cutting the median from about 35 hours to just 6 hours.25PubMed Central. Efficacy of prednisolone in children hospitalized for recurrent wheezing Whether this applies consistently across EV-D68 strains has not been confirmed in large trials.
For immunocompromised patients with persistent enterovirus infections, intravenous immunoglobulin (IVIg) has been the most commonly used therapy, administered in about 81% of a case series of patients receiving anti-CD20 antibody therapy who developed severe enterovirus illness. Other treatments used in small numbers included fluoxetine, pocapavir, and pleconaril, though none are approved for this indication.26RMD Open. Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies
In the lab, several classes of antiviral compounds show activity against EV-D68. Protease inhibitors targeting the viral 3C enzyme are among the most potent, outperforming older drugs like pleconaril in cell-culture studies.27PubMed Central. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68 A capsid-binding compound called R856932 has demonstrated potent activity against multiple contemporary strains by blocking viral uncoating.28PubMed Central. A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68 None of these have reached clinical trials in humans for EV-D68 specifically, so they remain experimental for now.
Vaccine Efforts
The absence of a vaccine against EV-D68 is a major gap in pediatric infectious-disease preparedness. The virus was recently designated a prototype pathogen within its family because of its rapid evolution, respiratory spread, and the scarcity of vaccine candidates in development.29PubMed Central. A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models Two main approaches are in preclinical stages. One uses virus-like particles (VLPs), essentially empty protein shells that look like the virus but contain no genetic material and cannot cause infection. A VLP based on the predominant B3 subclade has been tested in early laboratory studies.30Communications Biology. Structural insights from vaccine candidates for EV-D68
The other approach uses self-amplifying RNA, a platform similar to mRNA vaccines but designed to produce more protein from less RNA. In animal studies, this vaccine triggered strong neutralizing antibody responses in both mice and nonhuman primates and prevented respiratory and neurological disease in mice. Researchers also used the platform to map the antigenic diversity across the six known EV-D68 genotypes, informing how a multivalent vaccine might be composed to cover the breadth of circulating strains.31PubMed Central. A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models Both approaches are still in early stages, and the virus’s genetic variability means any eventual vaccine will need to cover multiple lineages.
Hand Sanitizer May Not Be Enough
Enteroviruses are non-enveloped viruses, which makes them considerably harder to kill with standard alcohol-based hand sanitizers than enveloped viruses like influenza or SARS-CoV-2. Studies on related enteroviruses have shown that widely used hand sanitizers based on 70% ethanol or isopropanol have poor effectiveness, and even 95% ethanol cannot fully inactivate some strains.32PubMed. Efficacy of alcohols and alcohol-based hand disinfectants against human enterovirus 71 Testing of laboratory-formulated alcohol-based sanitizers against related enteroviruses found that none met adequate inactivation thresholds for Enterovirus A71, even when they worked against poliovirus. High-level disinfectants performed better, but these are hospital-grade products not typically found in homes or schools.33PubMed. Resistance of poliovirus 1 and enterovirus A71 against alcohol and other disinfectants
The practical implication is that during EV-D68 season, soap and water handwashing is more reliable than a squirt of hand sanitizer. For surface disinfection in childcare and healthcare settings, products with activity against non-enveloped viruses should be chosen deliberately rather than assuming any all-purpose cleaner will do the job.
Viral Evolution and Why Strains Keep Changing
EV-D68 has diversified into multiple genetic clades, and the strains responsible for recent epidemics look substantially different from the virus originally described in 1962. Genomic analysis has identified dozens of amino acid substitutions distinguishing the B3 subclade, which has dominated recent outbreaks, from earlier B1 and B2 subclades. Some of these substitutions sit in regions of the virus that interact with host cells or with antiviral drugs.34PubMed Central. Molecular evolution and the global reemergence of enterovirus D68 by genome-wide analysis Other mutations have been found at protease cleavage sites within the viral genome, potentially altering how efficiently the virus replicates and spreads.35Scientific Reports. Whole-Genome Sequence Analysis Reveals the Enterovirus D68 Isolates during the United States 2014 Outbreak Mainly Belong to a Novel Clade
Global genomic surveillance shows that EV-D68 became the dominant enterovirus strain in North America by the mid-2000s, and its proportion of submissions increased in Europe, parts of Africa, and Asia between 2005 and 2010.36Biochemistry and Biophysics Reports. Global distribution and evolution of nine major non-polio enteroviruses revealed by genomic data mining This expansion matters because new clades carry different antigenic profiles, which complicates both natural immunity and vaccine design. A child who encountered clade A in one epidemic year may have limited cross-protection against a clade B3 strain two years later, contributing to the repeated waves of severe illness that define this syndrome.